


EnzymaticTherapy®
NATURAL MEDICINES™

February 26, 2003

1315 '03 MAR 19 P2:28

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740




RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Ivy Calm™	English Ivy (Hedera helix) Leaf Extract	Ivy Calm™ contains key saponins, known for their soothing effects.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.


By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 2/26/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer

Ivy Calm 6e

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

975 0162

LET 11499

83674

EnzymaticTherapy®

NATURAL MEDICINES™

February 27, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Ivy Calm™	English Ivy (Hedera helix) Leaf Extract	The ingredients in Ivy Calm™ have been carefully selected based upon research showing the benefits that they provide in supporting lung and bronchial passageway health.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.


By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 2/27/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer

Ivy Calm 7e

EnzymaticTherapy®
NATURAL MEDICINES™

February 28, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

MAR 10 2003


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Ivy Calm™	English Ivy (Hedera helix) Leaf Extract	The German Commission E has an approved monograph for ivy leaf for bronchial passageway support.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.


By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 2/28/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Ivy Calm 8e

EnzymaticTherapy®
NATURAL MEDICINES™

March 1, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Ivy Calm™	English Ivy (Hedera helix) Leaf Extract	A recent in vitro study confirms the antispasmodic activity in ivy.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 


Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 3/1/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Ivy Calm 9e

EnzymaticTherapy®

NATURAL MEDICINES™

March 3, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Ivy Calm™	English Ivy (Hedera helix) Leaf Extract	Saponins are glycosidic plant constituents. They have a bitter taste and are stimulating to the mucous membranes.* Their action is thought to be mediated by the gastric mucosa, which reflexively stimulates mucous glands in the bronchi via parasympathetic sensory pathways.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.


By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 3/3/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer

Ivy Calm 11e

EnzymaticTherapy®

NATURAL MEDICINES™

March 4, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

MAR 10 2003

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Ivy Calm™	English Ivy (Hedera helix) Leaf Extract	In an open trial, 26 children, aged 4 to 10 years, were given 1-2 teaspoons/day of an ivy leaf preparation for four weeks. The results indicated that the ivy leaf preparation was supportive of lung health. The effectiveness was also reflected in the spirometric examinations (measurement of air capacity of the lungs) and by auscultation (process of listening for lung sounds).*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: Robert C. Doster
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 3/4/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

A handwritten signature in black ink that reads "Michael P. Devereux". The signature is written in a cursive style with a large, prominent initial "M".

Michael P. Devereux
Chief Financial Officer

EnzymaticTherapy®

NATURAL MEDICINES™

March 5, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Ivy Calm™	English Ivy (Hedera helix) Leaf Extract	In a comparative, double-blind, randomized and controlled study involving 99 patients, age 25 to 70 years, ivy leaf drops were tested against a synthetic mucolytic (ambroxol). The efficacy was evaluated using both spirometry and auscultation. After four weeks of treatment, the drops were found as effective as the synthetic preparation in supporting lung health.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 

Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 3/5/03

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313


Fax: 888-570-6460

www.enzy.com

Ivy Calm 13e

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

A handwritten signature in black ink that reads "Michael P. Devereux". The signature is written in a cursive style with a large, prominent initial "M".

Michael P. Devereux
Chief Financial Officer

EnzymaticTherapy®

NATURAL MEDICINES™

March 6, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Ivy Calm™	English Ivy (Hedera helix) Leaf Extract	Most recently, a randomized, double-blind, crossover study involving 25 children, 10 to 15 years of age, was reported. The lung health effects over a period of 10 days was shown to be clinically relevant and statistically significant after the administration of any ivy leaf pediatric syrup or ivy leaf drop.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 

Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 3/6/03

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313


Fax: 888-570-6460

www.enzy.com

Ivy Calm 14e

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

A handwritten signature in black ink that reads "Michael P. Devereux". The signature is written in a cursive style with a large, prominent initial "M".

Michael P. Devereux
Chief Financial Officer

EnzymaticTherapy®

NATURAL MEDICINES™

March 7, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Ivy Calm™	English Ivy (Hedera helix) Leaf Extract	In a multicenter, post-marketing surveillance study, an ivy leaf syrup was shown to be a very well tolerated and effective agent in the support of lung health, in children aged 5 to 15 years, according to the subjective assessment by experienced pediatricians. The results of this study were positive for ivy syrup's beneficial effects.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: Robert C. Doster
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 3/7/03


825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313
Fax: 888-570-6460

Ivy Calm 15e

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

A handwritten signature in black ink, appearing to read "Michael P. Devereux". The signature is fluid and cursive, with a large initial "M" and a distinct "P" and "D".

Michael P. Devereux
Chief Financial Officer